Publicaciones en colaboración con investigadores/as de University of British Columbia (20)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization

    International Journal of Molecular Sciences, Vol. 24, Núm. 10

2022

  1. Developing a Diagnostic Multivariable Prediction Model for Urinary Tract Cancer in Patients Referred with Haematuria: Results from the IDENTIFY Collaborative Study

    European Urology Focus, Vol. 8, Núm. 6, pp. 1673-1682

  2. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies

    The Lancet. Haematology, Vol. 9, Núm. 5, pp. e374-e384

2021

  1. Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients

    International Journal of Cancer, Vol. 149, Núm. 2, pp. 327-336

  2. Left atrial appendage occlusion in chicken-wing anatomies: Imaging assessment, procedural, and clinical outcomes of the “sandwich technique”

    Catheterization and Cardiovascular Interventions, Vol. 97, Núm. 7, pp. E1025-E1032

  3. The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer – a multicentre observational study

    BJU International, Vol. 128, Núm. 4, pp. 440-450

  4. Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19

    New England Journal of Medicine, Vol. 385, Núm. 9, pp. 790-802

2019

  1. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

    European Journal of Immunology, Vol. 49, Núm. 10, pp. 1457-1973

2018

  1. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalanprednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

    Haematologica, Vol. 103, Núm. 9, pp. 1518-1526

  2. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies

    The Lancet Haematology, Vol. 5, Núm. 11, pp. e563-e598

  3. Rituximab plus lenalidomide in advanced untreated follicular lymphoma

    New England Journal of Medicine, Vol. 379, Núm. 10, pp. 934-946

2016

  1. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial

    The Lancet, Vol. 387, Núm. 10027, pp. 1551-1560

  2. Left atrial appendage occlusion with the AMPLATZER Amulet device: An expert consensus step-by-step approach

    EuroIntervention, Vol. 11, Núm. 13, pp. 1512-1521

2010

  1. Quality, quantity and harmony: The DataSHaPER approach to integrating data across bioclinical studies

    International Journal of Epidemiology, Vol. 39, Núm. 5, pp. 1383-1393

1989

  1. Regulation of in vitro PWM-induced IgG secretion in humans

    Cellular Immunology, Vol. 118, Núm. 2, pp. 435-447

1988

  1. Changes in Immune Function in Relapsing Multiple Sclerosis Correlate with Disease Activity As Assessed by Magnetic Resonance Imaging

    Annals of the New York Academy of Sciences, Vol. 540, Núm. 1, pp. 597-601

1987

  1. Reduction of immunoglobulin G secretion in vitro following long term lymphoblastoid interferon (Wellferon) treatment in multiple sclerosis patients

    Clinical and Experimental Immunology, Vol. 67, Núm. 1, pp. 66-75

1986

  1. Progressive multiple sclerosis: Abnormal immune functions in vitro and aberrant correlation with enumeration of lymphocyte subpopulations

    Journal of Neuroimmunology, Vol. 12, Núm. 1, pp. 37-48

1985

  1. Reduced in vitro IgG secretion following in vivo injection of interferon in multiple sclerosis (MS) patients

    Federation Proceedings, Vol. 44, Núm. 6